All posts by: Michael Zand

About Michael Zand

Stem Cell Therapy for Pain Management – Clinical Pain Advisor (registration)

Continue reading

2017-09-08 NEWS

Clinical Pain Advisor (registration)

Stem Cell Therapy for Pain Management
Clinical Pain Advisor (registration)
LAS VEGAS – In a presentation at PAINWeek 2017, held September 5-9, Jay Joshi, MD, CEO and medical director of the National Pain Centers in Vernon Hills, Illinois, gave on overview of stem cell therapies used in regenerative medicine to treat a number

Continue reading

2017-09-08 NEWS

MIT Technology Review

Amid Setback, Researchers Forge Ahead with “Off-the-Shelf” Immune Cells to Treat Cancer
MIT Technology Review
The highly personalized treatment, called CART therapy, uses a patient’s own immune cells and takes about three weeks to manufacture—two factors that lend to its $475,000 price tag. Similar therapies are in the pipeline, but the cost and time it

Continue reading

2017-09-08 NEWS

MIT Technology Review

Patient Death Won’t Slow Research on “Off-the-Shelf” Immune Cells to Treat Cancer
MIT Technology Review
The highly personalized treatment, called CART therapy, uses a patient’s own immune cells and takes about three weeks to manufacture—two factors that lend to its $475,000 price tag. Similar therapies are in the pipeline, but the cost and time it

Continue reading

2017-09-08 NEWS

THERE’S A NEW STEM CELL SHERIFF IN TOWN
Bloomberg BNA
Tough words from new FDA Commissioner Scott Gottlieb last week to describe stem cell clinics that have popped up around the country and, according to the agency, peddle unapproved, unproven, and even dangerous regenerative medicine products.

Continue reading

2017-09-08 NEWS

Cancer Research UK

Viruses may boost immunotherapy success
Cancer Research UK
It’s thought that viruses could be used to increase the proportion of patients who respond to immunotherapy drugs by drawing the attention of the immune system to the cancer. “They see that there’s an increase in the ‘heat’ of the tumour when the virus

Continue reading

2017-09-08 NEWS

Cancer Immunotherapy May Be Improved If Tregs Are Deftly Impaired
Genetic Engineering & Biotechnology News
The balancing act that is cancer immunotherapy requires that the body’s antitumor response be given a boost, but not too much of a boost. For example, simply getting rid of Tregs, the regulatory T cells that moderate the immune system’s attack on

Continue reading

2017-09-08 NEWS

Cancer Immunotherapy Developers Raise Nearly $150M in Financing
Genetic Engineering & Biotechnology News
A pair of cancer immunotherapy developers have raised a combined nearly $150 million in Series B financings toward development of new platform technologies, treatments, and facilities. Gritstone Oncology, which aims initially to develop tumor-specific …

Continue reading

2017-09-08 NEWS

Reuters

Cancer mutation gains ground as test for immunotherapy drugs
Reuters
MADRID (Reuters) – Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair. Research
Roche blood test could help ‘personalize’ cancer immunotherapyWHTC
ESMO17: Foundation biomarker test could help boost immunotherapyBioPharma Dive
Roche hopes blood test will predict immunotherapy efficacypharmaphorum
PharmaTimes
all 9 news articles »